Abstract
TG-1701 is a BTK inhibitor that was evaluated as monotherapy and in combination with ublituximab and umbralisib in a dose-escalation trial (Abstract 7......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
